A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.

Evaxion Biotech A/S has announced promising new data on its personalized cancer vaccine, EVX-01, highlighting that 80% of the vaccine's targets elicited a tumor-specific immune response, significantly ...

(RTTNews) - Greenwich LifeSciences, Inc. (GLSI) Wednesday reported preliminary positive immune response data from FLAMINGO-01 Phase 3 study evaluating GLSI-100, an immunotherapy to prevent breast ...

GLSI-100 treatment in HER2-positive breast cancer patients shows increased immune responses, with visible skin reactions indicating efficacy. Both HLA-A*02 and non-HLA-A*02 patients exhibited immune ...

Three days post viral infection CD8 T cells (red) re-arrest with antigen presenting cells (cyan), where they are supplied with IL-2 by CD4 T cells (yellow), which migrate in a stop and go pattern. The ...

Combination of Keytruda ® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

Novavax, Inc. (NASDAQ:NVAX) announced results Wednesday of the initial cohort of its COVID-19-Influenza Combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) ...

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS ...

Sepsis remains a major challenge in modern medicine, claiming millions of lives each year. For decades, clinical management has largely focused on suppressing excessive inflammation. Yet many patients ...